Please login to the form below

Not currently logged in
Email:
Password:

Hal Barron

This page shows the latest Hal Barron news and features for those working in and with pharma, biotech and healthcare.

GSK buys cancer firm Tesaro for $5.1bn

GSK buys cancer firm Tesaro for $5.1bn

GSK’s head of R&D Hal Barron said that PARP inhibitors are “important medicines that have been under appreciated in terms of the impact they can have on cancer patients”,

Latest news

More from news
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Kevin Sin joins GSK Kevin Sin joins GSK

    years. Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. ... Sin will report to Hal Barron and will be based at the group’s San Francisco office.

  • Levinson resigns from Roche board Levinson resigns from Roche board

    He has served as CEO at Calico, Google's health research business, since its formation in September 2013 and has since been joined by former Genentech/Roche colleagues Hal Barron, David

  • Roche CMO joins Google health venture Calico Roche CMO joins Google health venture Calico

    Hal Barron among four new appointments. Dr Hal Barron has left his role as chief medical officer of Swiss pharma company Roche to join Google's recently-launched health research arm ... Dr Barron is one of four new recruits from industry and academia to

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics